drugset / Trial / NCT06624319
Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to bupivacaine in U.S guided TAP block for preemptive analgesia In patients undergoing lower abdominal cancer surgeries.
Timeline
- Start
- 2025-01
- Primary completion
- 2026-01
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexmedetomidine | Other / unclassified | 0.5 ug/kg | Other |
| Comparator | Dexmedetomidine | Other / unclassified | 1.5 ug/kg | Other |
| Comparator | Bupivacaine | Other / unclassified | 0.25 % | Other |
| Comparator | Bupivacaine | Other / unclassified | 20 ml | Other |
Indications
No indication recorded.